|
|
| | Zanamivir-13C,15N2 (hydrate) Basic information |
| | Zanamivir-13C,15N2 (hydrate) Chemical Properties |
| solubility | Water: slightly soluble |
| | Zanamivir-13C,15N2 (hydrate) Usage And Synthesis |
| Description | Zanamivir-13C,15N2 is intended for use as an internal standard for the quantification of zanamivir (Item No. 15123) by GC- or LC-MS. Zanamivir is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.1 It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50 values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50 values ranging from 0.6 to 7.9 nM in vitro. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza.WARNING This product is not for human or veterinary use. | | References | [1] ELLIOTT M. Zanamivir: from drug design to the clinic.[J]. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 10 1: 1885-1893. DOI: 10.1098/rstb.2001.1021 |
| | Zanamivir-13C,15N2 (hydrate) Preparation Products And Raw materials |
|